MENS (Jyong Biotech Ltd) Utang jangka cendhak marang modal

The primary threats to Jyong Biotech Ltd (MENS) are prolonged certification timelines for plant-based remedies and pressure from synthetic analogs. The business faces stringent regulatory oversight and complexities in patenting formulas for urology. This chart of current share prices, where the metric stands at 0.00, highlights the stock's dependence on breakthroughs in treating sexual dysfunction and expansion into Asian markets.

This indicator compares short-term liabilities to equity, measuring the dependence of operating activities on short-term debt financing. For Jyong Biotech Ltd (MENS), whose success depends on regulatory approvals and product commercialization, a stable history of the short-term loan-to-equity ratio confirms financial resilience while establishing a risky economic moat.